Efficacy and safety of preoperative preparation with Lugol's iodine solution in euthyroid patients with Graves' disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial.

BACKGROUND: Currently, both the American Thyroid Association and the European Thyroid Association recommend preoperative preparation with Lugol's Solution (LS) for patients undergoing thyroidectomy for Graves' Disease (GD), but their recommendations are based on low-quality evidence. The LIGRADIS trial aims to provide evidence either to support or refute the systematic use of LS in euthyroid patients undergoing thyroidectomy for GD. METHODS: A multicenter randomized controlled trial will be performed. Patients ≥18 years of age, diagnosed with GD, treated with antithyroid drugs, euthyroid and proposed for total thyroidectomy will be eligible for inclusion. Exclusion criteria will be prior thyroid or parathyroid surgery, hyperparathyroidism that requires associated parathyroidectomy, thyroid cancer that requires adding a lymph node dissection, iodine allergy, consumption of lithium or amiodarone, medically unfit patients (ASA-IV), breastfeeding women, preoperative vocal cord palsy and planned endoscopic, video-assisted or remote access surgery.Between January 2020 and January 2022, 270 patients will be randomized for either receiving or not preoperative preparation with LS. Researchers will be blinded to treatment assignment. The primary outcome will be the rate of postoperative complications: hypoparathyroidism, recurrent laryngeal nerve injury, hematoma, surgical site infection or death. Secondary outcomes will be intraoperative events (Thyroidectomy Difficulty Scale score, blood loss, recurrent laryngeal nerve neuromonitoring signal loss), operative time, postoperative length of stay, hospital readmissions, permanent complications and adverse events associated to LS. CONCLUSIONS: There is no conclusive evidence supporting the benefits of preoperative treatment with LS in this setting. This trial aims to provide new insights into future Clinical Practice Guidelines recommendations. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03980132.

Adrenalectomía laparoscópica: presentación de 43 casos / Laparoscopic adrenalectomy: Presentation of 43 cases

Introducción El propósito del estudio es exponer y analizar nuestra experiencia en adrenalectomía laparoscópica (AL).Material y métodos Estudio descriptivo y retrospectivo sobre AL realizada en nuestro centro desde enero de 2000 hasta diciembre de 2008.ResultadosSe realizaron un total de 43 AL a 41 pacientes mediante abordaje transperitoneal lateral. La mediana de edad de los pacientes intervenidos se situó en 53 años. La principal indicación en frecuencia de nuestra serie fue el hiperaldosteronismo (19), seguido de incidentalomas (8), feocromocitomas (6), síndrome de Cushing (6), lesiones metastásicas (3) y carcinoma suprarrenal primario (1). La media de estancia hospitalaria poscirugía fue de 3 días y la media del tamaño de las masas fue de 30mm (rango: 4–155mm). No hubo mortalidad en nuestra serie. La necesidad de conversión se redujo a un caso; en ningún caso fue necesario reintervenir a un paciente. ConclusionesLa AL es una técnica segura y eficaz en el tratamiento de tumores suprarrenales que puede realizarse con riesgo y morbilidad mínima (AU)

Introduction The aim of the study was to present and analyse our experience in laparoscopic adrenalectomy (LA).Materials and methods Descriptive and retrospective study including LA performed over 8 years, between 2000 and 2008 in our hospital. Results A total of 43 LA were performed to 41 patients using a transperitoneal lateral approach. Indications for adrenalectomy included hyperaldosteronism (19), non-functioning adenoma (8), phaeochromocytoma (6), Cushing's syndrome (6), metastasis (3) and adrenal primary tumour (1). Median postoperative hospital stay was 3 days and the median size of the masses was 30mm (range: 4–155mm) Complications occurred in 3 patients (2 respiratory infections, and 1 intraoperative bleeding). There was no mortality. Only one case needed conversion to open adrenalectomy; no patients required reintervention. Conclusion Laparoscopic adrenalectomy is a safe and effective method in the treatment of adrenal masses and it can be performed with minimal risk and morbidity (AU)

[Laparoscopic adrenalectomy: presentation of 43 cases]. / Adrenalectomía laparoscópica: presentación de 43 casos.

INTRODUCTION: The aim of the study was to present and analyse our experience in laparoscopic adrenalectomy (LA). MATERIALS AND METHODS: Descriptive and retrospective study including LA performed over 8 years, between 2000 and 2008 in our hospital. RESULTS: A total of 43 LA were performed to 41 patients using a transperitoneal lateral approach. Indications for adrenalectomy included hyperaldosteronism (19), non-functioning adenoma (8), phaeochromocytoma (6), Cushing's syndrome (6), metastasis (3) and adrenal primary tumour (1). Median postoperative hospital stay was 3 days and the median size of the masses was 30mm (range: 4-155mm) Complications occurred in 3 patients (2 respiratory infections, and 1 intraoperative bleeding). There was no mortality. Only one case needed conversion to open adrenalectomy; no patients required reintervention. CONCLUSION: Laparoscopic adrenalectomy is a safe and effective method in the treatment of adrenal masses and it can be performed with minimal risk and morbidity.